

Bibliografia

- [1] Nichols, D. E. (2016). *Psychedelics*. *April*, 264–355.
- [2] Swanson, L. R. (2018). Unifying theories of psychedelic drug effects. *Frontiers in Pharmacology*, 9(MAR), 1–23. <https://doi.org/10.3389/fphar.2018.00172>
- [3] Schultes, R. E. (1969). Hallucinogens of plant origin. *Science*, 163(3864), 245–254. <https://doi.org/10.1126/SCIENCE.163.3864.245/ASSET/DCDAF530-789D-45F6-9B7E-E08EE3AA57BD/ASSETS/SCIENCE.163.3864.245.FP.PNG>
- [4] Rucker, J. J. H., Iliff, J., & Nutt, D. J. (2018). Psychiatry & the psychedelic drugs. Past, present & future. *Neuropharmacology*, 142, 200–218. <https://doi.org/10.1016/j.neuropharm.2017.12.040>
- [5] Garcia-Romeu, A., & Richards, W. A. (2018). Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. *International Review of Psychiatry*, 30(4), 291–316. <https://doi.org/10.1080/09540261.2018.1486289>
- [6] Passie, T., Guss, J., & Krähenmann, R. (2022). Lower-dose psycholytic therapy – A neglected approach. *Frontiers in Psychiatry*, 13, 1020505. <https://doi.org/10.3389/FPSYT.2022.1020505/BIBTEX>
- [7] Sessa, B. (2018). The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant. *Psychopharmacology*, 235(2), 551–560. <https://doi.org/10.1007/S00213-017-4713-7/METRICS>
- [8] Andersen, K. A. A., Carhart-Harris, R., Nutt, D. J., & Erritzoe, D. (2021). Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. *Acta Psychiatrica Scandinavica*, 143(2), 101–118. <https://doi.org/10.1111/ACPS.13249>
- [9] Kozłowska, U., Nichols, C., Wiatr, K., & Figiel, M. (2022). From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders. *Journal of Neurochemistry*, 162(1), 89–108. <https://doi.org/10.1111/jnc.15509>
- [10] Teixeira, P. J., Johnson, M. W., Timmermann, C., Watts, R., Erritzoe, D., Douglass, H., Kettner, H., & Carhart-Harris, R. L. (2021). Psychedelics and health behaviour change. *Journal of Psychopharmacology*, 36(1), 12-19. <https://doi.org/10.1177/02698811211008554>
- [11] Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion

- mystical-type experiences having substantial and sustained personal meaning and spiritual significance. *Psychopharmacology*, *187*(3), 268–283.
<https://doi.org/10.1007/s00213-006-0457-5>
- [12] Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C., & Davis, A. K. (2020). Long-term effects of psychedelic drugs: A systematic review. *Neuroscience and Biobehavioral Reviews*, *113* (March), 179–189. <https://doi.org/10.1016/j.neubiorev.2020.03.017>
- [13] Hendricks, P. S., Thorne, C. B., Clark, C. B., Coombs, D. W., & Johnson, M. W. (2015). Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. *Journal of Psychopharmacology*, *29*(3), 280–288. <https://doi.org/10.1177/0269881114565653>
- [14] Bouso, J. C., Palhano-Fontes, F., Rodríguez-Fornells, A., Ribeiro, S., Sanches, R., Crippa, J. A. S., Hallak, J. E. C., de Araujo, D. B., & Riba, J. (2015). Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans. *European Neuropsychopharmacology*, *25*(4), 483–492. <https://doi.org/10.1016/j.euroneuro.2015.01.008>
- [15] Schindler, E. A. D., & Hendricks, P. S. (2023). Adapting psychedelic medicine for headache and chronic pain disorders. *Expert Review of Neurotherapeutics*, *23*(10), 867–882. <https://doi.org/10.1080/14737175.2023.2246655>
- [16] Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. *Journal of Psychopharmacology*, *30*(12), 1268–1278. <https://doi.org/10.1177/0269881116662634>
- [17] Evans, J., Robinson, O. C., Argyri, E. K., Suseelan, S., Murphy-Beiner, A., McAlpine, R., Luke, D., Michelle, K., & Prideaux, E. (2023). Extended difficulties following the use of psychedelic drugs: A mixed methods study. *PLOS ONE*, *18*(10), e0293349. <https://doi.org/10.1371/JOURNAL.PONE.0293349>
- [18] Lutkajtis, A., & Evans, J. (2023). Psychedelic integration challenges: Participant experiences after a psilocybin truffle retreat in the Netherlands. *Journal of Psychedelic Studies*, *6*(3), 211–221. <https://doi.org/10.1556/2054.2022.00232>
- [19] Robinson, O., Evans, J., Luke, D., McAlpine, R., Sahely, A., Fisher, A., Sundeman, S., Ketzitidou-Argyri, E., Murphy-Beiner, A., Michelle, K., & Prideaux, E. (2024). Coming

- Back Together: A Qualitative Survey Study of Coping and Support Strategies Used by People to Cope With Extended Difficulties After the Use of Psychedelic Drugs. *SSRN Electronic Journal*. <https://doi.org/10.2139/SSRN.4687209>
- [20] Aixalà, M. (2023). *Psychedelic Integration: Psychotherapy for Non-Ordinary States of Consciousness*. Synergetic Press. <https://www.amazon.co.uk/Psychedelic-Integration-Psychotherapy-Non-Ordinary-Consciousness-ebook/dp/B09PZ5K299>
- [21] Halpern, J. H., Lerner, A. G., & Passie, T. (2018). A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD. *Current Topics in Behavioral Neurosciences*, 36, 333–360. https://doi.org/10.1007/7854_2016_457/COVER
- [22] Carhart-Harris, R. L., & Friston, K. J. (2019). REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics. *Pharmacological Reviews*, 71(3), 316–344. <https://doi.org/10.1124/pr.118.017160>
- [23] Gorman, I., Nielson, E. M., Molinar, A., Cassidy, K., & Sabbagh, J. (2021). Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice. *Frontiers in Psychology*, 12(March), 1–16. <https://doi.org/10.3389/fpsyg.2021.645246>
- [24] Phelps, J. (2017). Developing Guidelines and Competencies for the Training of Psychedelic Therapists. *Journal of Humanistic Psychology*, 57(5), 450–487. <https://doi.org/10.1177/0022167817711304>
- [25] Yaden, D. B., Potash, J. B., & Griffiths, R. R. (2022). Preparing for the Bursting of the Psychedelic Hype Bubble. *JAMA Psychiatry*, 79(10), 943–944. <https://doi.org/10.1001/JAMAPSYCHIATRY.2022.2546>
- [26] Sexton, J. D., Crawford, M. S., Sweat, N. W., Varley, A., Green, E. E., & Hendricks, P. S. (2019). Prevalence and epidemiological associates of novel psychedelic use in the United States adult population. <https://doi.org/10.1177/0269881119827796>, 33(9), 1058–1067. <https://doi.org/10.1177/0269881119827796>
- [27] Killion, B., Hai, A. H., Alsolami, A., Vaughn, M. G., Sehun Oh, P., & Salas-Wright, C. P. (2021). LSD use in the United States: Trends, correlates, and a typology of us. *Drug and Alcohol Dependence*, 223, 108715. <https://doi.org/10.1016/J.DRUGALCDEP.2021.108715>
- [28] Bathje, G. J., Majeski, E., & Kudowor, M. (2022). Psychedelic integration: An analysis of the concept and its practice. *Frontiers in Psychology*, 13, 824077.

<https://doi.org/10.3389/FPSYG.2022.824077/BIBTEX>

- [29] Butlen-Ducuing, F., McCulloch, D. E. W., Haberkamp, M., Mattila, T., Bałkowiec-Iskra, E., Aislaitner, G., Balabanov, P., Lundberg, J., Stenbæk, D. S., Elferink, A., Knudsen, G. M., & Thirstrup, S. (2023). The therapeutic potential of psychedelics: the European regulatory perspective. *The Lancet*, *401*(10378), 714–716. [https://doi.org/10.1016/S0140-6736\(23\)00264-7](https://doi.org/10.1016/S0140-6736(23)00264-7)
- [30] Greń, J., Tylš, F., Lasocik, M., & Kiraly, C. (2023). Back from the rabbit hole. Theoretical considerations and practical guidelines on psychedelic integration for mental health specialists. *Frontiers in Psychology*, *14*, 1054692. <https://doi.org/10.3389/FPSYG.2023.1054692/BIBTEX>
- [31] Earleywine, M., Low, F., Lau, C., & De Leo, J. (2022). Integration in Psychedelic-Assisted Treatments: Recurring Themes in Current Providers’ Definitions, Challenges, and Concerns. *Journal of Humanistic Psychology*. <https://doi.org/10.1177/00221678221085800>
- [32] Nichols, D. E., Nichols, C. D., & Hendricks, P. S. (2023). Proposed Consensus Statement on Defining Psychedelic Drugs. <https://Home.Liebertpub.Com/Psymed>, *1*(1), 12–13. <https://doi.org/10.1089/PSYMED.2022.0008>
- [33] van Elk, M., & Yaden, D. B. (2022). Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review. *Neuroscience & Biobehavioral Reviews*, *140*, 104793. <https://doi.org/10.1016/J.NEUBIOREV.2022.104793>
- [34] Carhart-Harris, Robin L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014). The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs. *Frontiers in Human Neuroscience*, *8*(1 FEB), 1–22. <https://doi.org/10.3389/fnhum.2014.00020>
- [35] de Vos, C. M. H., Mason, N. L., & Kuypers, K. P. C. (2021). Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. *Frontiers in Psychiatry*, *12* (September). <https://doi.org/10.3389/fpsy.2021.724606>
- [36] Majić, T., Schmidt, T. T., & Gallinat, J. (2015). Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences? *Journal of Psychopharmacology*, *29*(3), 241–253. <https://doi.org/10.1177/0269881114568040>

- [37] Davis, A. K., Barrett, F. S., & Griffiths, R. R. (2020). Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. *Journal of Contextual Behavioral Science*, *15*, 39–45.
<https://doi.org/10.1016/J.JCBS.2019.11.004>
- [38] Zinberg, N. (1984). *Drug, Set, and Setting: The Basis for Controlled Intoxicant Use*. Yale University Press
- [39] Carhart-Harris, Robin L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018). Psychedelics and the essential importance of context. *Journal of Psychopharmacology*, *32*(7), 725–731. <https://doi.org/10.1177/0269881118754710>
- [40] Olson, J. A., Suissa-Rochelleau, L., Lifshitz, M., Raz, A., & Veissière, S. P. L. (2020). Tripping on nothing: placebo psychedelics and contextual factors. *Psychopharmacology*, *237*(5), 1371–1382. <https://doi.org/10.1007/s00213-020-05464-5>
- [41] Ona, G. (2018). Inside bad trips: Exploring extra-pharmacological factors. *Journal of Psychedelic Studies*, *2*(1), 53–60. <https://doi.org/10.1556/2054.2018.001>
- [42] Johnson, M. W., Richards, W. A., & Griffiths, R. R. (2008). Human hallucinogen research: Guidelines for safety. *Journal of Psychopharmacology*, *22*(6), 603–620.
<https://doi.org/10.1177/0269881108093587>
- [43] Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2017). Neuroticism is associated with challenging experiences with psilocybin mushrooms. *Personality and Individual Differences*, *117*, 155–160. <https://doi.org/10.1016/j.paid.2017.06.004>
- [44] Nielson, E. M., & Guss, J. (2018). The influence of therapists' first-hand experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training. *Journal of Psychedelic Studies*, *2*(2), 64–73. <https://doi.org/10.1556/2054.2018.009>
- [45] Hendy, K. (2022). What Can the Chemical Hold?: The Politics of Efficacy in the Psychedelic Renaissance. *Culture, Medicine and Psychiatry*, *46*(2), 322–343.
<https://doi.org/10.1007/S11013-021-09708-7/METRICS>
- [46] Zhang, D., Lee, E. K. P., Mak, E. C. W., Ho, C. Y., & Wong, S. Y. S. (2021). Mindfulness-based interventions: an overall review. *British Medical Bulletin*, *138*(1), 41–57.
<https://doi.org/10.1093/BMB/LDAB005>
- [47] Kurtz, R. (2015). *Body-Centered Psychotherapy: The Hakomi Method (Revised ed.)*. LifeRhythm.
- [48] Grof, S. (2014). Holotropic breathwork: A new experiential method of psychotherapy

- and self-exploration. *Journal of Transpersonal Research*, 6(1), 7–24.
- [49] Roseman, L., Ron, Y., Saca, A., Ginsberg, N., Luan, L., Karkabi, N., Doblin, R., & Carhart-Harris, R. (2021). Relational Processes in Ayahuasca Groups of Palestinians and Israelis. *Frontiers in Pharmacology*, 12, 607529. <https://doi.org/10.3389/FPHAR.2021.607529/BIBTEX>
- [50] Guss, J. R., Krause, R., & J. Sloschower. (2020). Yale Manual for Psilocybin-Assisted Therapy of Depression. *The Library of Congress*. <https://doi.org/10.31234/osf.io/u6v9y>
- [51] Pilecki, B., Luoma, J. B., Bathje, G. J., Rhea, J., & Narloch, V. F. (2021). Ethical and legal issues in psychedelic harm reduction and integration therapy. *Harm Reduction Journal*, 18(1), 1–14. <https://doi.org/10.1186/s12954-021-00489-1>
- [52] Tatarsky, A. (2003). Harm reduction psychotherapy: Extending the reach of traditional substance use treatment. *Journal of Substance Abuse Treatment*, 25(4), 249–256. [https://doi.org/10.1016/S0740-5472\(03\)00085-0](https://doi.org/10.1016/S0740-5472(03)00085-0)
- [53] Fadiman, J. (2019). *Przewodnik psychodelicznego podróżnika: bezpieczne, terapeutyczne i święte podróże* (M. Lorenc, Tłum.). Wydawnictwo Cień Kształtu. (Oryginał został opublikowany w 2011 r.)
- [54] Westrum, R., & Dufrechou, J. (2019). *The Psychedelics Integration Handbook*. Ryan P. Westrum & Jay P. Dufrechou.
- [55] Carvalho, M. C., De Sousa, M. P., Frango, P., Dias, P., Carvalho, J., Rodrigues, M., & Rodrigues, T. (2014). Crisis intervention related to the use of psychoactive substances in recreational settings - evaluating the Kosmicare project at boom festival. *Current Drug Abuse Reviews*, 7(2), 81–100. <https://doi.org/10.2174/1874473708666150107115515>
- [56] Mian, M. N., Altman, B. R., Low, F., & Earleywine, M. (2023). Development of the Protective Strategies for Psychedelics Scale: A novel inventory to assess safety strategies in the context of psychedelics. *Journal of Psychopharmacology*. <https://doi.org/10.1177/02698811231214060>
- [57] Greń, J., Gorman, I., Ruban, A., Tylš, F., Bhatt, S., & Aixelà, M. (2023). Call for evidence-based psychedelic integration. *Experimental and Clinical Psychopharmacology*. <https://doi.org/10.1037/PHA0000684>